Dr. Parth Shah, the Director of Vascular and Endovascular Surgery at the Thoracic Outlet Center at Hartford Healthcare’s Heart and Vascular institute asked XVIVO to create an animation of a surgery he performs to relieve a condition called thoracic outlet syndrome, or TOS. The details of the surgery were difficult to convey in regular conversation and diagramming …
Your Mouth, in Sickness and Health
By
Michael Astrachan
XVIVO Scientific Animation recently wrapped up an exciting project on the bacteria that are found in the human mouth and how these bacteria are affected by oral hygiene (or the lack thereof). We teamed up again with colleagues at Johnson & Johnson for a new virtual reality (VR) visualization of the normal bacterial community that …
Start-up with Style: Launch your Visuals with XVIVO
By
Michael Astrachan
As the saying goes, a picture is worth a thousand words. Start-up pharmaceutical and biotech companies often need to create illustrations, investigational candidate images, and animations to provide rich scientific detail on a disease state, a process, or a mechanism of action for their website, for presentations, and for printed materials. XVIVO Scientific Animation is …
Illustrating the Unconventional: PROTAC™ Technology for Disease Therapy
By
Michael Astrachan
XVIVO, in collaboration with Wyant Simboli and their client, Arvinas Inc., helped communicate the unconventional mechanism of action for a new class of drugs that engage the body’s own protein disposal system to target cancers and other difficult-to-treat diseases. PROTAC™ PLATFORM Arvinas’ approach is to tag a protein implicated in a disease with their proprietary Proteolysis-Targeting Chimera, …
XVIVO Founder on UCONN VR Panel
By
Michael Astrachan
This week, XVIVO’s Founder and Creative Director, Michael Astrachan, spoke on an invited panel of guests at UCONN’s Science Salon to discuss “Seeing Things: Virtual Reality Hits Mainstream.” Michael was honored to speak alongside the other accomplished panelists: Patrick Belinger, Creator of NovaSwarm; Horea Ilies, Professor of Mechanical Engineering at UCONN; and Zach Stone, Vice …
New Year, New Reel
By
Michael Astrachan
To kick-off the New Year, we’re launching a fresh new showreel for XVIVO. 2018 was an exciting and rewarding year for the team at XVIVO Scientific Animation. We delved into new topics, such as neuroendocrine tumors and ciliary motility, we expanded our capabilities in virtual reality and interactive experiences, and we completed hundreds of projects …
XVIVO Cheer
By
Michael Astrachan
XVIVO is in the holiday spirit! This past Saturday, the team at XVIVO got the opportunity to relax, unwind and celebrate another successful year together. Our team looked dapper and dressed up for the holiday season! Here are some of the highlights from this year’s XVIVO Holiday Party! Our audio director, Matt Berky, was under …
Snip, Snip: New Genome Editing Tools in Development
By
Michael Astrachan
The NIH Somatic Cell Genome Editing program is supporting development of new tools and tests that may one day bring more gene therapies to patients. What if a disease could be treated by diving into a cell to edit the DNA causing the disease? That may be a reality in the not-to-distant future for many …
Meet Michael Astrachan, XVIVO’s Founder and President
By
Michael Astrachan
From airbrushing t-shirts at malls around Connecticut to producing his own scientific illustration and animation studio, Michael Astrachan merged the logical left side of his brain with the creative right to establish XVIVO 17 years ago. He was chosen to tell his story and discuss his company’s development with WTNH’s Ann Nyberg; an interview made possible …
Demystifying the Lung Cancer Alphabet Soup
By
Michael Astrachan
A Focus On ALK-Positive Non-Small Cell Lung Cancer In partnership with Wedgewood Communications, XVIVO developed two videos for Takeda Oncology to discuss lung cancer mechanism of disease and treatments. This animation takes an extensive and detailed look at the sub-populations of patients who have non-small cell lung cancer (NSCLC), which affects about 198,000 new patients in the United States each …